SecBot SecBot
SECBOTREPLAY Home › Report › NVCR

NVCR · NovoCure reported 8% year-over-year revenue growth for Q4 and full year…

NovoCure Ltd · 8-K filed Feb 26, 2026 at 07:01 ET

At the news

MIXEDIMPACT 7/10

8-K filed Feb 26, 2026 at 07:01 ET

NovoCure reported 8% year-over-year revenue growth for Q4 and full year 2025, driven by increased active patients on therapy. The company received FDA approval for Optune Pax in locally advanced pancreatic cancer, a key milestone. Despite revenue growth, the company reported a net loss of $24.5 million in Q4 and guided for Adjusted EBITDA between -$20 million and $0 million in 2026 as it continues investing in clinical trials and commercialization.

  • Full year 2025 revenue was $655.4 million, up 8% YoY; Q4 revenue was $174.4 million, also up 8% YoY
  • FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026
  • Q4 2025 net loss was $24.5 million with loss per share of $0.22
  • Gross margin declined to 76% from 79% in prior year due to HFE array rollout, pre-reimbursement NSCLC costs, and tariffs

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access